Company overview

Genmab is a leading international biotechnology company that aims to improve the lives of patients by creating and developing innovative antibody products. The company was founded in Copenhagen, Denmark in 1999. Genmab’s ordinary shares are publicly traded on Nasdaq Copenhagen and American Depositary Shares under its ADR Program are listed in the United States on the Nasdaq Global Select Market. Genmab employs approximately 530 people at its headquarter in Denmark and at its core facilities in the Netherlands and the United States. In addition, Genmab has a regional office in Japan. 

Vial icon
2 marketed products
DARZALEX® (daratumumab)
Arzerra® (ofatumumab)

Flask icon
Several proprietary clinical programs


Technology icon
4 proprietary technologies
DuoBody® platform
HexaBody® technology
DuoHexaBody® platform
HexElect® platform

Test tubes icon
Robust pre-clinical pipeline

 Antibody icon

World-class antibody and R&D expertise

 Globe iconBuilding commercial expertise

 Investigation-RGB-140pxStrategic collaborations

Document-RGB-140px
Solid financials